Vertex: More Appealing At A Lower Price, But Don't Rush In (Rating Upgrade)
Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...
Vertex Pharmaceuticals says VX-264 study did not meet primary endpoint
Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...
Vertex: Expectations Reset With Improved Fundamentals (Rating Upgrade)
Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...
Zacks Investment Research on MSN4d
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
pharmaphorum4d
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Investing Snacks5d
Vertex Flexes Muscles Beyond Cystic Fibrosis
Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...
Investing Snacks4d
Painfully Profitable: Vertex’s Shot Beyond CF
Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...